All In Biotech

NDA 209569 · Dutch Ophthalmic

Tissueblue

Brilliant Blue G · Ophthalmic · Disclosing Agent

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Apr 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Dec 20, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2

1 Phase 3, 0 recruiting

FAERS reports

21

16 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 17, 2026.

Indications & Usage TissueBlue 0.025% is indicated to selectively stain the internal limiting membrane (ILM). TissueBlue 0.025% is a disclosing agent indicated to selectively stain the internal limiting membrane (ILM).

Mechanism: Mechanism of action Brilliant Blue G has been shown to selectively stain the ILM, but not the epiretinal membrane nor the retina, making it easier to visualize the membrane for removal, although the exact mechanism of this selectivity has not been elucidated.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 20, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
  • TISSUEBLUE · BRILLIANT BLUE G 0.025% · SOLUTION, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Brilliant Blue G" as an intervention, any sponsor and status, largest first.

All 2 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • disability3
  • visual impairment3
  • blindness2
  • non-infectious endophthalmitis2
  • toxic anterior segment syndrome2
  • adverse drug reaction1
  • drug hypersensitivity1
  • endophthalmitis1
  • eye disorder1
  • eye injury1
  • hemianopia1
  • impaired quality of life1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
20203
20214
20225
20233
20242
20252
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 21 on PubMed

Sponsor: Dutch Ophthalmic

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.